摘要
抗有丝分裂物质结合中在秋水仙素的微管蛋白抗是重要的抗肿瘤和血管破坏剂。吡啶类和吖嗪在药物化学是是享有特权的支架,并且近年来许多秋水仙碱站点配体(CSL)已将其纳入到自己的结构以提高其药代动力学和药效学性质的目的。秋水仙碱站点配体已根据它们的化学结构和含有抗肿瘤化合物吡啶和吡啶化学结构分类进行了描述。还讨论了结构修饰背后的设计原则和取得的夹杂在这些杂环化合物其生物活性效果。吸取成就和失败的经验教训,并为描绘出未来的观点。
关键词: 吖嗪、吡啶、抗有丝分裂物质,微管蛋白,秋水仙碱、抗肿瘤、药物设计。
Current Medicinal Chemistry
Title:Pyridine Based Antitumour Compounds Acting at the Colchicine Site
Volume: 23 Issue: 11
Author(s): R. Álvarez, L. Aramburu, P. Puebla, E. Caballero, M. González, A. Vicente, M. Medarde, R. Peláez
Affiliation:
关键词: 吖嗪、吡啶、抗有丝分裂物质,微管蛋白,秋水仙碱、抗肿瘤、药物设计。
摘要: Antimitotics binding at the colchicine site of tubulin are important antitumour and vascular disrupting agents. Pyridines and azines are privileged scaffolds in medicinal chemistry and in recent years many colchicine site ligands (CSL) have incorporated them into their structures with the aim of improving their pharmacokinetic and pharmacodynamics properties. CSL have been classified according to their chemical structures and the chemical structures of the pyridine and azine containing antimitotic compounds are described. The designed principles behind the structural modifications and the achieved effect on the biological activity upon inclusion of these heterocycles are also discussed. Lessons from the achievements and failures have been extracted and future perspectives delineated.
Export Options
About this article
Cite this article as:
R. Álvarez, L. Aramburu, P. Puebla, E. Caballero, M. González, A. Vicente, M. Medarde, R. Peláez , Pyridine Based Antitumour Compounds Acting at the Colchicine Site, Current Medicinal Chemistry 2016; 23 (11) . https://dx.doi.org/10.2174/092986732311160420104823
DOI https://dx.doi.org/10.2174/092986732311160420104823 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanotechnology in Neuroscience and its Perspective as Gene Carrier
Current Topics in Medicinal Chemistry Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry The Disposal of Reactive Carbonyl Species through Carnosine Conjugation: What We Know Now
Current Medicinal Chemistry Purine Analogues as Kinase Inhibitors: A Review
Recent Patents on Anti-Cancer Drug Discovery Central Nervous System Neoplasms in Hong Kong: An Inscription of Local Studies
Current Cancer Therapy Reviews DAB389EGF Fusion Protein Therapy of Refractory Glioblastoma Multiforme
Current Pharmaceutical Biotechnology Subject Index to Volume 2
Current Neuropharmacology Novel Cell Nucleus Directed Fluorescent Tetraazacyclododecane-Tetraacetic Acid Compounds
Medicinal Chemistry Polymer-Based Drug Delivery Devices for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Protein Kinase C Pharmacology: Perspectives on Therapeutic Potentials as Antidementic and Cognitive Agents
Recent Patents on CNS Drug Discovery (Discontinued) Techniques and Methods for In Vivo MRI Monitoring of Exogenous and Endogenous Neural Stem Cell-Mediated Brain Repair
Recent Patents on Regenerative Medicine Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization
Anti-Cancer Agents in Medicinal Chemistry The Possibility of Novel Antiplatelet Peptides: The Physiological Effects of Low Molecular Weight HSPs on Platelets
Current Pharmaceutical Design mTOR Inhibition and the Tumor Vasculature
Current Angiogenesis (Discontinued) New Alkyl-Lipid Blockers of SK3 Channels Reduce Cancer Cell Migration and Occurrence of Metastasis
Current Cancer Drug Targets TGFb and its Smad Connection to Cancer
Current Genomics Trends and Topics in CD133 in Pubmed From 2000 to 2015
Current Biomarkers (Discontinued) Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design Nanodiamonds as a New Horizon for Pharmaceutical and Biomedical Applications
Current Drug Delivery